Aprea Therapeutics targets Q4 2026 clinical data readout for APR-1051 Phase 1 ACESOT-1051 trial

• Aprea outlined plans to accelerate enrollment in its Phase 1 ACESOT-1051 dose-escalation trial of WEE1 inhibitor APR-1051.
• Early single-agent activity was observed with a favorable tolerability profile, without reporting detailed efficacy or safety metrics.
• Next clinical results are scheduled for presentation at a medical meeting in Q4 2026.
• Development focus shifts toward uterine serous carcinoma, cyclin E-overexpressing platinum-resistant ovarian cancer, supported by an expansion to at least 50 patients.
• New combination arms are planned in HPV-positive head and neck cancer, colorectal cancer, using dose levels that have already cleared safety review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300800PRIMZONEFULLFEED9800612) on July 30, 2026, and is solely responsible for the information contained therein.